ADC Therapeutics SA
1.44USD
-0.1600 (-10.00%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ADCT.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 20 | 30 | 16 | 18 | 17 | 18 | 18 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -25 | -25 | -18 | -31 | -44 | -28 | -32 | -36 |
| Net Income | -17 | -33 | -6 | -41 | -57 | -39 | -31 | -44 |
| EPS (Diluted) | -$0.11 | -$0.21 | $0.02 | -$0.30 | -$0.50 | -$0.36 | -$0.27 | -$0.42 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)